Diagnostic Accuracy of Urinary N Terminal pro-B Type Natriuretic Peptides for Hemodynamically Significant-Patent Ductus Arteriosus in Preterm Infants

Neonatology. 2024;121(1):1-6. doi: 10.1159/000533824. Epub 2023 Oct 27.

Abstract

Background: Echocardiography is the gold standard for the diagnosis hemodynamically significant-patent ductus arteriosus (hs-PDA). It requires trained personnel and is not readily available. Urinary biomarkers can be used as an adjunct.

Objective: The objective of this study was to systematically review the diagnostic accuracy of urinary N terminal pro-B type natriuretic peptides (NT-proBNP) for hs-PDA in preterm neonates.

Methods: We included studies that evaluated urinary NT-proBNP and urinary NT-proBNP/creatinine ratio (index tests) in preterm neonates with hs-PDA (participants) in comparison with echocardiogram (reference standard). Methodological quality and certainty of evidence were assessed using Quality Assessment of Diagnostic-Accuracy Studies (QUADAS-2) and Grading of Recommendations Assessment, Development and Evaluation (GRADE), respectively.

Results: Low quality of evidence suggests that urinary NT-proBNP has modest sensitivity and specificity for the diagnosis of a hs-PDA, with variation in accuracy based on assay and patient characteristics.

Conclusion: Urinary NT-proBNP assays must be locally validated for specific patient populations and further studies to support its use must be performed.

Keywords: Echocardiography; Natriuretic peptides; Neonates; Patent ductus arteriosus; Urinary biomarker.

Publication types

  • Systematic Review

MeSH terms

  • Biomarkers
  • Ductus Arteriosus, Patent* / diagnostic imaging
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature*
  • Natriuretic Peptide, Brain
  • Peptide Fragments

Substances

  • pro-brain natriuretic peptide (1-76)
  • Natriuretic Peptide, Brain
  • Peptide Fragments
  • Biomarkers